Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (Q1)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -50.33%22.25M | -17.27%85.1M | 4.05%44.79M | 30.26%102.87M | 23.97%43.05M | 153.43%78.97M | 184.84%34.73M | 158.98%31.16M | 527.16%12.19M | 783.42%6.56M |
| Operating income | -50.33%22.25M | -17.27%85.1M | 4.05%44.79M | 30.26%102.87M | 23.97%43.05M | 153.43%78.97M | 184.84%34.73M | 158.98%31.16M | 527.16%12.19M | 783.42%6.56M |
| Cost of sales | 55.54%-6.83M | 20.43%-30.8M | 6.21%-15.36M | -28.69%-38.71M | -30.36%-16.37M | -142.86%-30.08M | -134.65%-12.56M | -140.30%-12.39M | -538.78%-5.35M | -907.32%-2.89M |
| Operating expenses | 55.54%-6.83M | 20.43%-30.8M | 6.21%-15.36M | -28.69%-38.71M | -30.36%-16.37M | -142.86%-30.08M | -134.65%-12.56M | -140.30%-12.39M | -538.78%-5.35M | -907.32%-2.89M |
| Gross profit | -47.62%15.42M | -15.37%54.3M | 10.35%29.44M | 31.23%64.16M | 20.35%26.68M | 160.41%48.89M | 224.13%22.17M | 172.99%18.78M | 518.35%6.84M | 705.27%3.66M |
| Selling expenses | 43.00%-22.67M | 10.49%-74.9M | -3.77%-39.78M | 3.58%-83.67M | 10.07%-38.33M | 13.86%-86.78M | 4.78%-42.63M | -97.51%-100.75M | -172.96%-44.77M | -210.88%-20.57M |
| Administrative expenses | 53.37%-16.63M | 24.12%-68.16M | 25.99%-35.66M | 17.52%-89.83M | 13.37%-48.19M | 25.16%-108.91M | -5.10%-55.63M | -87.24%-145.52M | -80.41%-52.93M | -41.78%-20.2M |
| Research and development expenses | 89.62%-17.99M | 2.12%-251.76M | -21.18%-173.26M | 17.34%-257.21M | 9.66%-142.98M | 27.24%-311.17M | 42.42%-158.26M | -290.05%-427.66M | -665.90%-274.84M | -696.30%-67M |
| Revaluation surplus | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 29.89%-427.98M | 116.99%12.61M | 82.75%-17.29M |
| -Changes in the fair value of derivative financial instruments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 266.08%34.45M | 985.17%34.45M | 357.75%7.1M |
| -Changes in the fair value of other assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 21.58%-462.44M | 71.76%-21.85M | 74.97%-24.39M |
| Impairment and provision | ---- | ---87.99M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other impairment is provision | ---- | ---87.99M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Special items of operating profit | 538.90%102.88M | -65.56%-5.53M | -115.38%-23.44M | 82.07%-3.34M | 10.69%-10.88M | -302.60%-18.64M | -216.69%-12.19M | 3,934.17%9.2M | 12,332.14%10.44M | 10,949.45%9.87M |
| Operating profit | 125.14%61.01M | -17.34%-434.04M | -13.57%-242.7M | 22.39%-369.89M | 13.32%-213.7M | 55.62%-476.61M | 28.05%-246.53M | -27.52%-1.07B | -121.62%-342.65M | 13.61%-111.52M |
| Financing cost | 61.28%-1.77M | 4.07%-8.58M | -2.47%-4.57M | -30.38%-8.95M | -79.65%-4.46M | -122.90%-6.86M | -59.31%-2.48M | 20.50%-3.08M | 26.47%-1.56M | 41.10%-844K |
| Earning before tax | 123.96%59.24M | -16.84%-442.62M | -13.34%-247.27M | 21.64%-378.84M | 12.39%-218.16M | 55.11%-483.48M | 27.66%-249.01M | -27.30%-1.08B | -119.62%-344.2M | 13.92%-112.36M |
| After-tax profit from continuing operations | 123.96%59.24M | -16.84%-442.62M | -13.34%-247.27M | 21.64%-378.84M | 12.39%-218.16M | 55.11%-483.48M | 27.66%-249.01M | -27.30%-1.08B | -119.62%-344.2M | 13.92%-112.36M |
| Earning after tax | 123.96%59.24M | -16.84%-442.62M | -13.34%-247.27M | 21.64%-378.84M | 12.39%-218.16M | 55.11%-483.48M | 27.66%-249.01M | -27.30%-1.08B | -119.62%-344.2M | 13.92%-112.36M |
| Profit attributable to shareholders | 123.96%59.24M | -16.84%-442.62M | -13.34%-247.27M | 21.64%-378.84M | 12.39%-218.16M | 55.11%-483.48M | 27.66%-249.01M | -27.30%-1.08B | -119.62%-344.2M | 13.92%-112.36M |
| Basic earnings per share | 124.14%0.14 | -16.85%-1.04 | -13.73%-0.58 | 21.93%-0.89 | 13.56%-0.51 | 90.03%-1.14 | 87.39%-0.59 | 7.30%-11.43 | 79.55%-4.68 | |
| Diluted earnings per share | 124.14%0.14 | -16.85%-1.04 | -13.73%-0.58 | 21.93%-0.89 | 13.56%-0.51 | 90.03%-1.14 | 87.39%-0.59 | 7.30%-11.43 | 79.55%-4.68 | |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | Guowei Certified Public Accountants Co., Ltd. | -- | Ernst & Young | -- | Ernst & Young Accounting Firm | -- | Ernst & Young Accounting Firm | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.